North Korea on May 21 reported more than 200,000 new patients suffering from fever for a fifth consecutive day, as the country fought its first confirmed coronavirus outbreak.
Moderna Inc. plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently waive the company’s COVID-19 vaccine patents for shots intended for certain low-income and middle-income countries.
The wind howls and new-fallen leaves swirl around. There’s a sense of dread hanging in the air. Monsters are about, spreading terror across the land. The sound of coughing and gasping breath is coming up fast. A slow look over your shoulder reveals the sweaty, nightmare visage of Covid-19 – or does it?
AbbVie and Harvard University entered into a $30 million collaborative research alliance to develop therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.
Recently published scientific studies include research into whether Covid-19 immunity might not be possible.
The U.S. Food and Drug Administration approved Ilaris (canakinumab) injection for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease.
Shares of Gilead Sciences Inc. rose 10 percent after a report that patients with COVID-19 treated with the company’s experimental drug, remdesivir, in a clinical trial showed rapid recovery in fever and respiratory symptoms.
Gilead Sciences Inc.’s shares surged 16 percent in after-hours trading on Thursday following a media report detailing encouraging partial data from trials of the U.S. company’s experimental drug remdesivir in severe COVID-19 patients.
The U.S. Food and Drug Administration approved drugmaker Merck & Co.’s Ebola vaccine Ervebo, the first FDA-authorized vaccine against the deadly virus.
